康华生物拟增资及受让纳美信股权，最终实现对其全资控股

Core Viewpoint - Kanghua Biotech plans to acquire 100% equity of Nameixin Biotech to enhance its mRNA technology platform and accelerate vaccine development efficiency [1] Group 1: Acquisition Details - The company intends to subscribe to the new registered capital of Nameixin and acquire existing shares from current shareholders [1] - Upon completion of the transaction, Kanghua Biotech will hold 100% equity in Nameixin [1] Group 2: Strategic Implications - The acquisition will improve the company's biopharmaceutical strategic layout and accelerate the construction of advanced technology platforms [1] - The transaction is expected to enhance core competitiveness and leverage synergies in research, clinical, production, and commercialization between Kanghua Biotech and Nameixin [1] - It will expedite the industrialization process of in-development products and optimize resource allocation efficiency [1]